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SHORT COMMUNICATION
Growth inhibition observed following administration of an LHRH agonist
to a clonal variant of the MCF-7 breast cancer cell line is accompanied
by an accumulation of cells in the GO/Gi phase of the cell cycle.
P. Mullen, W.N. Scott & W.R. Miller
I.C.R.F., Medical Oncology Unit, Western General Hospital, Edinburgh, EH4 2XU, UK.
LHRH is a hypothalamic hormone which stimulates the
release of gonadotrophins from the pituitary (Fraser & Baird,
1987). Recently, synthetic analogues of LHRH have been
developed, some of which have agonist properties (Fraser,
1982). Acute administration of such agonists stimulates gon-
adotrophin release but when given chronically paradoxical
effects are produced in that gonadotrophin levels fall (Manni
et al., 1986). A consequence of chronic administration is that
trophic effects on the ovary are supressed and a form of
medical castration results. This has led to the concept of
using LHRH agonists to treat premenopausal women with
hormone-dependant metastatic breast cancer (Klijn et al.,
1984; Walker et al., 1986; Williams et al., 1986).
Whilst the major anti-tumour effects of LHRH agonists in
premenopausal women with breast cancer are probably med-
iated through blockade of the pituitary-gonadal axis, direct
inhibitory effects of LHRH agonists on breast cancers are
also possible. In this respect, it is of interest that (i) LHRH
agonists can have beneficial effects in postmenopausal women
(Waxman et al., 1985) in whom the effects of LHRH agonists
on circulating estrogens are minimal (Plowman et al., 1986),
(ii) LHRH binding sites may be detected in both primary
breast tumours and breast cancer cell lines (Eidne et al.,
1985; Fekete et al., 1989), and (iii) certain breast cancer cell
lines can be inhibited by LHRH agonists in culture (Miller et
al., 1985; Blankenstein et al., 1985; Wiznitzer & Benz, 1984).
However, the latter observations are controversial, others
being unable to demonstrate direct effects on tumour cells
(Wilding et al., 1987; Scambia et al., 1988; Slotman et al.,
1989). The aim of the study was therefore to investigate
further the effects of an LHRH agonist on cellular prolifera-
tion and cell cycle kinetics in several MCF-7 breast cancer
cell lines.
Four subclones of MCF-7 cells were investigated. One cell
line was obtained directly from the Michigan Cancer Found-
ation and maintained in Dulbecco's minimum essential me-
dium (DMEM) as described previously (Miller et al., 1985).
These LHRH-sensitive cells were designated MCF-7 (ls) and
were studied in their 193rd passage. A variant clone of
MCF-7 (ls) was derived in another laboratory who cultured
MCF-7 (ls) cells for 13 passages in similar culture media but
supplemented with a different source of foetal calf serum
(Wilding et al., 1987). On return to our laboratory these cells
were found to be LHRH insensitive, were designated MCF-7
(li), and used in their 209th pasage. Two further MCF-7
clones were obtained from Dr M.E. Lippman at NIH,
Bethesda and used in their 53rd and > 1000th passage (desig-
nated NIH (A) and NIH (B) respectively).
All cells were routinely maintained at 37°C in 'Cel-cult'
tissue culture flasks (Sterilin Ltd, England) in DMEM sup-
plemented with heat-inactivated foetal calf serum (10%),
sodium bicarbonate (16 mM) and penicillin/streptomycin un-
der a humidified atmosphere of 5% CO2: 95% air.
In growth experiments, 0.5 x 106 log phase cells were
plated out in 60 mm petri dishes in the presence or absence
of the LHRH agonist Buserelin (Hoescht 766). Medium was
replaced daily. Cells were harvested at days 1, 2, 3 and 4 by
first removing culture medium, washing with EDTA in
phosphate-buffered saline (0.02%, 1 ml) and then incubating
with trypsin (0.05%, 4 ml) for 10 min at 37°C. Cells were
then counted with a haemocytometer. After trypsinisation,
cells were resuspended in 200 ,sl of citrate buffer and stored
at - 40°C prior to flow cytometric DNA analysis (Vindel0v
et al., 1983a). All experiments were carried out in triplicate
and on more than one occasion.
Nuclei were prepared as described by Vindel0v et al.
(1983b), with minor modifications. Cell suspensions (t0.5 x 106
cells) were digested by mixing with trypsin (0.003%, 450 p1l)
and leaving at room temperature for 10min. Trypsin inhib-
itor (0.05% w/v) and RNAase (0.01% w/v) in a final volume
of 375 p1 were then added and left for a further 10 min.
Finally, the cells were stained on ice with propidium iodide
(416tig/ml ') and spermine tetrahydrochloride (1.16 mgml-')
in a final volume of 250ytL. Cell suspensions were passed
through a gauge 23 needle prior to analysis to minimise
clumping. Cellular DNA content was measured using an
EPICS-C flow cytometer (Coulter Electronics Ltd). A DNA
histogram was created from 10,000 cellular events. The pro-
portion of cells in each of the phases of the cell cycle was
determined using the 'Para 1' program supplied by Coulter
Electronics.
The effect of Buserelin on the growth of the four MCF-7
clones under investigation is shown in Figure 1. Throughout
the four days culture, Buserelin showed a reproducible dose-
dependant reduction of cellular proliferation in the MCF-7
(ls) line such that at a concentration of 10-6 M there was a
net decrease in cell number (Figure la) over the study period.
In contrast, no significant effects on cell number were ob-
served in the three other MCF-7 clones (Figures lb-d),
including the MCF-7 (li) clone which was originally derived
from the MCF-7 (ls) cells. Cell cycle analysis of MCF-7 (ls)
cells cultured in the absence of LHRH agonist showed com-
paratively minor changes throughout the culture period.
There was nevertheless a tendency for the proportion of cells
in GO/GI phase to increase by day 4 at the expense of those
in both S and G2/M (Figure 2a). In the presence of LHRH
agonist however, the inhibitory effect observed in MCF-7 (ls)
cells was accompanied by major changes in cell cycle dis-
tribution; the inclusion of LHRH agonist produced a marked
increase in the percentage of cells in the GO/GI resting phase
of the cell cycle at days 2, 3 and 4. This increase was
accompanied by a concommitant decrease in the percentage
of cells in both the S and G2/M phases of the cell cycle. Like
growth inhibition, these effects were dose-dependant. In the
absence of LHRH agonist, MCF-7 (li) cells showed a similar
cell cycle distribution to the MCF-7 (ls) cells during the early
stages of culture, although at days 2 and 3 there was a
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tendency for more MCF-7 (ii) cells to be in GO/Gi phase
(Figure 2b). In contrast to the effects observed in the MCF-7
(Is) cell line, Buserelin produced no consistent effect on the
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Figure 1 Effect of the LHRH agonist Buserelin on the cellular
proliferation of four subclones of MCF-7 cells: a, MCF-7 (Is), b,
MCF-7 (li), c, MCF-7 NIH'A' and d, MCF-7 NIH 'B'. Each time
point represents the mean of triplicate cultures from a represen-
tative experiment.
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cell cycle kinetics of MCF-7 (li) cells, regardless of the
agonist concentration or time point of culture.
These results confirm our previous report that the LHRH
agonist Buserelin is capable of inhibiting MCF-7 cells in
culture (Miller et al., 1985). The present data further extend
these studies by indicating that (a) the inhibitory action of
Buserelin on cell numbers is associated with effects on cell
cycle kinetics, and (b) these effects are evident in only one of
four clones of MCF-7 cells investigated. These observations
have several important implications.
Firstly, the results would explain the inability of certain
groups to detect direct effects of LHRH agonist on MCF-7
cells (Wilding et al., 1987; Scambia et al., 1988; Slotman et
al., 1989). It is clear that not all populations of cells desig-
nated 'MCF-7' are sensitive to LHRH agonist. Whilst such
heterogeneity of response has been noted in MCF-7 cells for
other parameters (Berg et al., 1984; Butler et al., 1986),
sensitivity to LHRH agonist seems to be a particularly un-
stable phenotype. Thus the MCF-7 (li) cells which are insen-
sitive to LHRH agonist were derived from the MCF-7 (ls) by
maintenance in a different laboratory for a relatively short
number of passages. This transition was not associated with
any obvious change in morphology or cellular characteristics
other than the doubling time of about 35 h in MCF-7 (ls)
was reduced to about 29 h in MCF-7 (li). Of the four clones
investigated the MCF-7 (ls) were the slowest growing and it
may be that a slow cellular proliferation rate is necessary
before Buserelin can exert anti-proliferative effects.
The other major finding was that in the MCF-7 (ls) cells
inhibitory effects of LHRH agonist were associated with
marked changes in the cell cycle kinetics. A dose-dependant
increase in the proportion of GO/GI cells and concommitant
reduction in the proportion of cells in both the S and G2/M
phases of the cell cycle was observed over the 4 day study
period. Such effects would be consistent with the LHRH
agonist either encouraging cells to leave the cell cycle or
inhibiting recruitment into the active stages of the cell cycle.
We have been unable to detect high affinity binding sites
for LHRH or its agonist in any of the cell lines despite using
several different species of LHRH and synthetic agonists.
Furthermore, although low affinity binding sites have been
found (Miller et al., 1985), these were present in both
LHRH-sensitive and insensitive cell lines. There is therefore
little evidence in favour of inhibitory effects on cellular pro-
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Figure 2 Percentage of cells present in the three major phases of the cell cycle (GO/G1, S and G2/M) following administration of
LHRH agonist to MCF-7 (ls) and MCF-7 (li) cells. Each time point represents the mean of triplicate cultures.
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liferation being mediated through binding sites for the agon-
ist.
In summary, we have confirmed that the LHRH agonist
Buserelin is capable of direct inhibitory effects on MCF-7
cells although such action is restricted to a clonal variant.
Furthermore, the dose-dependant inhibition of cellular pro-
liferation is accompanied by major changes in the cell cycle
kinetics, resulting in an accumulation of cells in the GO/GI
phase of the cell cycle. This phenomenon does not appear to
be mediated via specific high-affinity receptor sites.
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